Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Modigene has appointed Phillip Frost as chairman of its board of directors.
Subscribe to our email newsletter
The company also announced the appointments of two new directors, Marian Gorecki and Steven Rubin, and the departures of current board chairman and director Eugene Bauer and current director Joel Kanter.
Dr Frost currently serves as chairman and CEO of Opko Health, a publicly-traded specialty healthcare company. He also serves as chairman of Ladenburg Thalmann & Co., as vice chairman of Teva Pharmaceuticals, and as a director of Northrop Grumman and Continucare Corporation.
Avri Havron, CEO of Modigene, said: “As the company now transitions into a clinical stage biopharmaceutical company, we believe the enhanced commitment of Dr Frost and the diverse, real-world clinical and commercial experience that he, Dr Gorecki and Mr Rubin bring will be of great value to Modigene and its shareholders.”